Combinational therapies for the treatment of advanced cervical cancer
A Duenas-Gonzalez - Expert Opinion on Pharmacotherapy, 2023 - Taylor & Francis
Introduction From a therapeutic standpoint, invasive cervical cancer can be designated as
early, locally advanced, and advanced stages. Systemic treatment remains the primary …
early, locally advanced, and advanced stages. Systemic treatment remains the primary …
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?
I Vergote, I Ray-Coquard, D Lorusso… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Recurrent or primary advanced metastatic cervical cancer (R/M CC) has a poor
prognosis with a 5-year-survival rate of 16.5%, demanding novel and improved therapies for …
prognosis with a 5-year-survival rate of 16.5%, demanding novel and improved therapies for …
Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in recurrent or metastatic cervical Cancer: results from the innovaTV 205/GOG …
I Vergote, E Van Nieuwenhuysen… - Journal of clinical …, 2023 - ascopubs.org
PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by
tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in …
tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in …
An insight into synthesis and antitumor activity of citrate and gallate stabilizing gold nanospheres
MM Fathy, AA Elfiky, YS Bashandy, MM Hamdy… - Scientific Reports, 2023 - nature.com
Both gallic and citrate are well-established antioxidants that show promise as new selective
anti-cancer drugs. Gold nanoparticles (AuNPs) as well can be developed as flexible and …
anti-cancer drugs. Gold nanoparticles (AuNPs) as well can be developed as flexible and …
Clinical Significance of Soluble LAG-3 (sLAG-3) in Patients With Cervical Cancer Determined via Enzyme-Linked Immunosorbent Assay With Monoclonal Antibodies
Y Li, W Wang, J Tian, Y Zhou, Y Shen… - … in Cancer Research …, 2023 - journals.sagepub.com
Background: The tumor microenvironment and tumor immunity have become the focus of
research on tumor diagnosis and treatment. Lymphocyte activation gene-3 (LAG-3, CD223) …
research on tumor diagnosis and treatment. Lymphocyte activation gene-3 (LAG-3, CD223) …
Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the …
CA Sitler, C Tian, CA Hamilton, MT Richardson… - Cancers, 2024 - mdpi.com
Simple Summary Randomized clinical trials show a survival benefit associated with immuno-
molecular therapy (IMT) use in metastatic or recurrent cervical cancer. This study …
molecular therapy (IMT) use in metastatic or recurrent cervical cancer. This study …
Cervical cancer geographical burden analyzer: an interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic …
T Castellano, K Moore, J Ting, C Washington… - Gynecologic …, 2023 - Elsevier
Objective Cervical cancer (CC) disproportionately affects women based on socioeconomic
status and racial/ethnic background. There is limited research in quantifying and visualizing …
status and racial/ethnic background. There is limited research in quantifying and visualizing …
[HTML][HTML] Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims …
K Sonawane, T Castellano, C Washington… - Gynecologic oncology …, 2022 - Elsevier
Purpose Contemporary, real-world data on eligible patients receiving treatment following
progression on first-line (1L) recurrent or metastatic cervical cancer (r/mCC) therapy are …
progression on first-line (1L) recurrent or metastatic cervical cancer (r/mCC) therapy are …
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205 …
K Madsen, F Köse, A Jackson, I Boere… - Journal of Clinical …, 2023 - escholarship.org
PURPOSE: Tissue factor is highly expressed in cervical carcinoma and can be targeted by
tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in …
tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in …
Assessing Geographic Variation in Rates of Cervical Cancer and Recurrent or Metastatic Cervical Cancer Among Medicaid Enrollees
CA Leath III, J Nysenbaum, J Ting… - American Journal of …, 2023 - journals.lww.com
Objective: The objective of this study was to evaluate trends in prevalence of cervical cancer
(CC) and rates of recurrent or metastatic cervical cancer (r/mCC) treatment initiation at the …
(CC) and rates of recurrent or metastatic cervical cancer (r/mCC) treatment initiation at the …